MMP-14 and MMP-2 are key metalloproteases in Dupuytren's disease fibroblast-mediated contraction

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 6, 2012, Pages 897-905

  Wilkinson, Janine M ^a   Davidson, Rose K ^a   Swingler, Tracey E ^a   Jones, Eleanor R ^a   Corps, Anthony N ^b   Johnston, Phillip ^b   Riley, Graham P ^a   Chojnowski, Adrian J ^c   Clark, Ian M ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Collagen; Contraction; Dupuytren's disease; FPCL; MMP

Indexed keywords

ADAMTS1 PROTEIN; COLLAGEN; COLLAGENASE 3; GELATIN; GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; SMALL INTERFERING RNA; STROMELYSIN;

ARTICLE; COLLAGEN DEGRADATION; DISEASE COURSE; DUPUYTREN CONTRACTURE; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MUSCLE FIBER CONTRACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZYMOGRAPHY;

CELLS, CULTURED; DUPUYTREN CONTRACTURE; FASCIA; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; RNA INTERFERENCE; RNA, SMALL INTERFERING; VOLAR PLATE;

EID: 84859025945     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.02.001     Document Type: Article

References (55)

1. Hindocha S., McGrouther D.A., Bayat A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (N Y) 2009, 4:256-269.
2. Luck J.V. Dupuytren's contracture; a new concept of the pathogenesis correlated with surgical management. J. Bone Joint Surg. Am. 1959, 41-A:635-664.
3. O'Gorman D.B., Vi L., Gan B.S. Molecular mechanisms and treatment strategies for Dupuytren's disease. Ther. Clin. Risk Manag. 2010, 6:383-390.
4. Michou L., Lermusiaux J.L., Teyssedou J.P., Bardin T., Beaudreuil J., Petit-Teixeira E. Genetics of Dupuytren's disease. Joint Bone Spine 2012, 79:7-12.
5. Dolmans G.H., Werker P.M., Hennies H.C., Furniss D., Festen E.A., Franke L., Becker K., van der Vlies P., Wolffenbuttel B.H., Tinschert S., Toliat M.R., Nothnagel M., Franke A., Klopp N., Wichmann H.E., Nurnberg P., Giele H., Ophoff R.A., Wijmenga C. Wnt signaling and Dupuytren's disease. N. Engl. J. Med. 2011, 365:307-317.
6. Gilpin D., Coleman S., Hall S., Houston A., Karrasch J., Jones N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J. Hand Surg. Am. 2010, 35:2027-2038. (e2021).
7. Brinckerhoff C.E., Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 2002, 3:207-214.
8. Knauper V., Lopez-Otin C., Smith B., Knight G., Murphy G. Biochemical characterization of human collagenase-3. J. Biol. Chem. 1996, 271:1544-1550.
9. Ohuchi E., Imai K., Fujii Y., Satio H., Seiki M., Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagenase and other extracellular macromolecules. J. Biol. Chem. 1997, 272:2446-2451.
10. d'Ortho M.P., Will H., Atkinson S., Butler G., Messent A., Gavrilovic J., Smith B., Timpl R., Zardi L., Murphy G. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur. J. Biochem. 1997, 250:751-757.
11. Murphy G., Cockett M.I., Stephens P.E., Smith B., Docherty A.J.P. Stromelysin is an activator of procollagenase. J. Biochem. 1987, 248:265-268.
12. Porter S., Clark I.M., Kevorkian L., Edwards D.R. The ADAMTS metalloproteinases. Biochem. J. 2005, 386:15-27.
13. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 2002, 115:3719-3727.
14. Kashiwagi M., Tortorella M., Nagase H., Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 2001, 276:12501-12504.
15. Brown P.D. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin. Investig. Drugs 2000, 9:2167-2177.
16. Bird J., Montana J.G., Wills R.E., Baxter A.D., Owen D.A. Selective matrix metalloproteinase (MMP) inhibitors having reduced side-effects. Chem. Abstr. 1999, 129:225751.
17. Drummond A.H., Beckett P., Brown P.D., Bone E.A., Davidson A.H., Galloway W.A., Gearing A.J., Huxley P., Laber D., McCourt M., Whittaker M., Wood L.M., Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N. Y. Acad. Sci. 1999, 878:228-235.
18. Hutchinson J.W., Tierney G.M., Parsons S.L., Davis T.R.C. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J. Bone Joint Surg. Br. 1998, 80-B:907-908.
19. Smith S.P., Devaraj V.S., Bunker T.D. The association between frozen shoulder and Dupuytren's disease. J. Shoulder Elbow Surg. 2001, 10:149-151.
20. Schaer H. Die atiologie der periarthritis humeroscapularis. Ergeb. Chir. Orthop. 1936, 29:11.
21. Bunker T.D., Reilly J., Baird K.S., Hamblen D.L. Expression of growth factors, cytokines and matrix metalloproteinases in frozen shoulder. J. Bone Joint Surg. Br. 2000, 82:768-773.
22. Qian A., Meals R.A., Rajfer J., Gonzalez-Cadavid N.F. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004, 64:399-404.
23. Tarlton J.F., Meagher P., Brown R.A., McGrouther D.A., Bailey A.J., Afoke A. Mechanical stress in vitro induces increased expression of MMPs 2 and 9 in excised Dupuytrens disease tissue. J. Hand Surg. Br. 1998, 23B:297-302.
24. Ulrich D., Ulrich F., Piatkowski A., Pallua N. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease. Arch. Orthop. Trauma Surg. 2009, 129:1453-1459.
25. Johnston P., Chojnowski A.J., Davidson R.K., Riley G.P., Donell S.T., Clark I.M. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J. Hand Surg. Am. 2007, 32:343-351.
26. Johnston P., Larson D., Clark I.M., Chojnowski A.J. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J. Hand Surg. Am. 2008, 33:1160-1167.
27. Dallon J.C., Ehrlich H.P. A review of fibroblast-populated collagen lattices. Wound Repair Regen. 2008, 16:472-479.
28. Bisson M.A., Mudera V., McGrouther D.A., Grobbelaar A.O. The contractile properties and responses to tensional loading of Dupuytren's disease-derived fibroblasts are altered: a cause of the contracture?. Plast. Reconstr. Surg. 2004, 113:611-621.
29. Townley W.A., Cambrey A.D., Khaw P.T., Grobbelaar A.O. Matrix metalloproteinase inhibition reduces contraction by Dupuytren fibroblasts. J. Hand Surg. Am. 2008, 33:1608-1616.
30. Townley W.A., Cambrey A.D., Khaw P.T., Grobbelaar A.O. The role of an MMP inhibitor in the regulation of mechanical tension by Dupuytren's disease fibroblasts. J. Hand. Surg. Eur. Vol. 2009, 34:783-787.
31. Morrison C.J., Butler G.S., Rodriguez D., Overall C.M. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell Biol. 2009, 21:645-653.
32. Johnston P., Chojnowski A.J., Davidson R.K., Riley G.P., Donell S.T., Clark I.M. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J. Hand Surg. Am. 2007, 32:343-351.
33. Bergman I., Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal. Chem. 1963, 35:1961-1965.
34. Tomasek J.J., Haaksma C.J., Eddy R.J., Vaughan M.B. Fibroblast contraction occurs on release of tension in attached collagen lattices: dependency on an organised actin cytoskeleton and serum. Anat. Rec. 1992, 232:359-368.
35. Krause C., Kloen P., Ten Dijke P. Elevated transforming growth factor beta and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis Tissue Repair 2011, 4:14.
36. Moyer K.E., Banducci D.R., Graham W.P., Ehrlich H.P. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro. Plast. Reconstr. Surg. 2002, 110:187-193. (discussion 194-186).
37. Rayan G.M., Tomasek J.J. Generation of contractile forces by cultured Dupuytren's disease and normal palmar fibroblasts. Tissue Cell 1994, 26:747-756.
38. Tarpila E., Ghassemifar M.R., Wingren S., Agren M., Franzen L. Contraction of collagen lattices by cells from Dupuytren's nodules. J. Hand Surg. Br. 1996, 21:801-805.
39. Daniels J.T., Cambrey A.D., Occleston N.L., Garrett Q., Tarnuzzer R.W., Schultz G.S., Khaw P.T. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest. Ophthalmol. Vis. Sci. 2003, 44:1104-1110.
40. Scott K.A., Wood E.J., Karran E.H. A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. FEBS Lett. 1998, 441:137-140.
41. Yamamoto M., Tsujishita H., Hori N., Ohishi Y., Inoue S., Ikeda S., Okada Y. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J. Med. Chem. 1998, 41:1209-1217.
42. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
43. Kajita M., Itoh Y., Chiba T., Mori H., Okada A., Kinoh H., Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 2001, 153:893-904.
44. Endo K., Takino T., Miyamori H., Kinsen H., Yoshizaki T., Furukawa M., Sato H. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 2003, 278:40764-40770.
45. Tatti O., Vehvilainen P., Lehti K., Keski-Oja J. MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp. Cell Res. 2008, 314:2501-2514.
46. McQuibban G.A., Gong J.H., Tam E.M., McCulloch C.A., Clark-Lewis I., Overall C.M. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000, 289:1202-1206.
47. Ong V.H., Carulli M.T., Xu S., Khan K., Lindahl G., Abraham D.J., Denton C.P. Cross-talk between MCP-3 and TGFbeta promotes fibroblast collagen biosynthesis. Exp. Cell Res. 2009, 315:151-161.
48. Deryugina E.I., Bourdon M.A., Reisfeld R.A., Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res. 1998, 58:3743-3750.
49. Itoh Y. MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 2006, 58:589-596.
50. Sabeh F., Li X.Y., Saunders T.L., Rowe R.G., Weiss S.J. Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J. Biol. Chem. 2009, 284:23001-23011.
51. Sabeh F., Shimizu-Hirota R., Weiss S.J. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 2009, 185:11-19.
52. Holmbeck K., Bianco P., Caterina J., Yamada S., Kromer M., Kuznetsov S.A., Mankani M., Robey P.G., Poole A.R., Pidoux I., Ward J.M., Birkedal-Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
53. Suojanen J., Salo T., Koivunen E., Sorsa T., Pirila E. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol. Ther. 2009, 8:2362-2370.
54. Devy L., Huang L., Naa L., Yanamandra N., Pieters H., Frans N., Chang E., Tao Q., Vanhove M., Lejeune A., van Gool R., Sexton D.J., Kuang G., Rank D., Hogan S., Pazmany C., Ma Y.L., Schoonbroodt S., Nixon A.E., Ladner R.C., Hoet R., Henderikx P., Tenhoor C., Rabbani S.A., Valentino M.L., Wood C.R., Dransfield D.T. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009, 69:1517-1526.
55. Gooyit M., Lee M., Hesek D., Boggess B., Oliver A.G., Fridman R., Mobashery S., Chang M. Synthesis, kinetic characterization and metabolism of diastereomeric 2-(1-(4-phenoxyphenylsulfonyl)ethyl)thiiranes as potent gelatinase and MT1-MMP inhibitors. Chem. Biol. Drug Des. 2009, 74:535-546.